Peptide Therapy · Off-label for men · Central mechanism
PT-141
(Bremelanotide)
PT-141 works on the brain’s arousal pathway rather than blood flow — a genuinely different mechanism from Viagra® or Cialis®. It has real completed trial data in men, but it’s also FDA-approved only for a completely different population: women with low sexual desire. This page separates what’s actually been tested from what’s marketing.
Overview
What PT-141 actually is
PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin receptors — specifically MC3R and MC4R — in the hypothalamus. Rather than increasing blood flow to the penis the way PDE5 inhibitors do, it acts on the brain’s own desire and arousal circuitry.
Because it doesn’t depend on nitric oxide signaling, it’s discussed as a potential option for men whose ED involves impaired nitric oxide pathways — including some men who don’t respond well to PDE5 inhibitors alone.
PT-141 is derived from Melanotan II, a peptide originally studied as a sunless-tanning compound that unexpectedly caused sexual arousal and spontaneous erections during early testing. Bremelanotide was engineered to concentrate that arousal effect at MC3R/MC4R while reducing the MC1R-driven tanning response.
Bremelanotide is FDA-approved only as Vyleesi®, an as-needed injectable for hypoactive sexual desire disorder (HSDD) in premenopausal women — approved in 2019 following the RECONNECT Phase 3 trials in more than 1,200 women.
There is no FDA-approved bremelanotide product for men. All male use — for ED, low libido, or otherwise — is off-label, typically via compounded formulations from licensed compounding pharmacies rather than the approved Vyleesi® product itself.
What the actual trial data shows
Phase II results in men — real, but not confirmatory
A randomized, double-blind, placebo-controlled Phase II trial evaluated bremelanotide specifically in men with erectile dysfunction:
A separate study found that bremelanotide combined with sildenafil produced significantly enhanced erectile response compared to sildenafil alone — specifically in men who had not responded well to sildenafil monotherapy. This is a genuinely useful data point for a specific group of men, though it doesn’t change PT-141’s regulatory status for male use.
How it’s used
Administration and timing
Route
The FDA-approved Vyleesi® product is a subcutaneous injection. Compounded formulations used off-label in men are also commonly available as intranasal sprays, which were the route studied in the original male Phase II trials.
Onset
Studies report a dose-dependent erectile response, with effects typically described starting around 30 to 60 minutes after administration.
Not a daily medication
Like the approved Vyleesi® product for women, PT-141 is used on an as-needed basis rather than continuously. Dosing and frequency for off-label male use should be determined by a physician familiar with the compound, not by copying protocols found online.
Safety profile
What’s actually reported
Nausea is common enough to be worth setting expectations for — most men who experience it describe it as mild and short-lived, but it’s the most frequently cited reason for discontinuing the medication.
How it compares
PT-141 vs. PDE5 inhibitors
| Feature | PT-141 | Viagra® / Cialis® |
|---|---|---|
| Mechanism | Central — brain arousal pathway | Peripheral — blood flow |
| Requires arousal already present? | No — acts on desire itself | Yes |
| FDA-approved for men? | No | Yes |
| Human trial data in men | Phase II only | Decades of Phase III+ data |
| Common side effect | Nausea (~40%) | Headache, flushing |
| Can be combined? | Yes — enhances effect in PDE5i non-responders | — |
Is it right for you?
Who typically considers PT-141
Men with low sexual desire alongside erectile difficulty, not just a purely mechanical erection problem
Men who haven’t responded well to PDE5 inhibitors alone
Men who understand this is off-label, with Phase II-level (not Phase III) human evidence
Men comfortable with a real, common nausea side effect
Common questions
Frequently asked questions
Is PT-141 FDA-approved?
Bremelanotide is FDA-approved as Vyleesi®, but only for hypoactive sexual desire disorder in premenopausal women. There is no FDA-approved bremelanotide product for men — any male use is off-label, typically through compounding pharmacies.
How is PT-141 different from Viagra or Cialis?
PDE5 inhibitors work peripherally, increasing blood flow to the penis, but they require arousal to already be present to work. PT-141 works centrally on the brain’s desire and arousal pathways directly, which is why it’s discussed for both low libido and ED — including in men whose ED doesn’t respond well to PDE5 inhibitors alone.
Can PT-141 be combined with Viagra or Cialis?
A published study found bremelanotide combined with sildenafil produced significantly better erectile response than sildenafil alone, in men who hadn’t responded well to sildenafil by itself. This combination should be managed by a physician familiar with both medications rather than self-directed.
Why does PT-141 cause nausea?
Melanocortin receptor activation affects areas of the brain involved in nausea as well as arousal, which is why it’s a common side effect — reported in roughly 40% of users. It’s typically mild and transient, but it’s the most common reason people discontinue the medication.
Related
Other options to consider
Considering PT-141?
Given the off-label status and real but limited human data, a detailed conversation with a specialist matters here. Search our directory or ask in the forum first.
Key sources: FDA prescribing information for VYLEESI (bremelanotide), NDA 210557 · Diamond, Earle, Rosen, Willett & Molinoff, published Phase II trial data on bremelanotide for male erectile dysfunction, International Journal of Impotence Research
This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Bremelanotide is not FDA-approved for use in men; any male use is off-label. Always consult a licensed physician before pursuing any treatment. Vyleesi® is a registered trademark of Palatin Technologies. PhallusMD does not endorse specific providers or compounding pharmacies.
There are no reviews yet. Be the first one to write one.